ResearcherUniversity of Southern DenmarkActive in the last 2 years
Lars Henrik Jensen
Matched on ORCID iD 0000-0002-0020-1537; OpenAlex author ID A5040739416. Sources: ClinicalTrials.gov.
Their work
- Papers
- 6 (first author 2, last author 1)
- Trials
- 1
- Grants
- 0
- Labs led
- 1
- Collaborators
- 15
2019: 1 trial · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 4 papers · 2026: 1 paper
Papers 6
- Targeting Reactive Species Stress and Nutrient Sensing to Enhance NK-Cell Function: Mechanistic Strategies for Overcoming Pancreatic Cancer Progression and Res… First author DOI 10.3390/ijms27177893↗
- The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST. Co-author DOI 10.1158/1078-0432.ccr-25-0758↗
- Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2025.1568386↗
- Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy. Last author DOI 10.3390/ijms26020515↗
- Dysbiosis-NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical Outcomes. First author DOI 10.3390/ijms26020730↗
- Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15030897↗
Trials 1
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sara Fanijavadi · 3 shared papers, 2025–2026 · strength 1.59
- Paper Targeting Reactive Species Stress and Nutrient Sensing to Enhance NK-Cell Function: Mechanistic Strategies for Overcomi… DOI 10.3390/ijms27177893↗
- Paper Dysbiosis-NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical Outcomes. DOI 10.3390/ijms26020730↗
- Paper Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy. DOI 10.3390/ijms26020515↗
- Julia Sidenius Johansen · 3 shared papers, 2023–2025 · strength 0.60
- Paper The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST. DOI 10.1158/1078-0432.ccr-25-0758↗
- Paper Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal… DOI 10.3389/fonc.2025.1568386↗
- Paper Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers15030897↗
- Inna Markovna Chen · 3 shared papers, 2023–2025 · strength 0.60
- Paper The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST. DOI 10.1158/1078-0432.ccr-25-0758↗
- Paper Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal… DOI 10.3389/fonc.2025.1568386↗
- Paper Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers15030897↗
- Louise S. Rasmussen · 2 shared papers, 2025 · strength 0.42
- Paper The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST. DOI 10.1158/1078-0432.ccr-25-0758↗
- Paper Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal… DOI 10.3389/fonc.2025.1568386↗
- Astrid Zedlitz Johansen · 2 shared papers, 2023–2025 · strength 0.37
- Carsten Palnæs Hansen · 2 shared papers, 2023–2025 · strength 0.37
- Karen‐Lise Garm Spindler · 1 shared paper, 2025 · strength 0.23
- Morten Bækbo Ladekarl · 1 shared paper, 2025 · strength 0.23
- Sidsel C. Lindgaard · 1 shared paper, 2025 · strength 0.23
- Mette M. Steiniche · 1 shared paper, 2025 · strength 0.23
- Benjamin Emil Stubbe · 1 shared paper, 2025 · strength 0.19
- Stine Dam Henriksen · 1 shared paper, 2025 · strength 0.19
- Ole Thorlacius‐Ussing · 1 shared paper, 2025 · strength 0.19
- Per Pfeiffer · 1 shared paper, 2025 · strength 0.19
- Liva K. Stuhr · 1 shared paper, 2023 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.